title: [The incidence of hypothyroidism symptoms and risk factors for cardiovascular events in subclinical hypothyroidism].
abstract: The clinical significance of subclinical hypothyroidism (SH) has not been determined. There are different opinions with regard to symptoms and clinical consequences of SH as well as effectiveness of treatment. Aim of study was the analysis of incidence of hypothyroidism symptoms and selected cardiovascular risk factors in patients with SH in comparison to euthyroid individuals and the evaluation of the effect of treatment of SH on the above parameters.
  
  
  METHODS
  Fifty patients were included in the study: 25 with SH, 25 in euthyreosis (C). The incidence of hypothyroidism symptoms and metabolic syndrome (MS), as well as total cholesterol (TCH), LDL, HDL triglycerides (TGL), glucose levels, values of systolic (SBP) and diastolic (DBP) blood pressure and the relationship between these factors and laboratory indexes of SH intensity were analyzed. Moreover, the risk of cardiovascular mortality (RCM) with the application of the HeartSCORE Risk Chart was evaluated. After a period of six months a similar analysis in the SH group was conducted; all the patients were administered L-thyroxin (mean dose +/- SD: 67.5 +/- 32.1 microg).
  
  
  RESULTS
  The mean number of hypothyroidism symptoms was higher in SH than in C group (SH: 8.4 +/- 3.2 vs. C: 1.7 +/- 1.5, p < 0.0005). Normalization of TSH observed in 17 patients resulted in a decrease in the mean number of symptoms (9.1 +/- 2.8 vs. 5.9 +/- 2.9, p < 0.0001). There were not differences between groups in the incidence of the MS and MS components and also the RCM. However only in SH group a positive correlations between TSH and BMI, TSH and age, age and TCH and LDL levels and SBP DBP values and also between TSH and the RCM were noted. Normalization of TSH level resulted in a decrease in the RCM (p = 0.055).
  
  
  CONCLUSIONS
  Treatment of SH might bring potential benefits; it might lessen symptoms and reduce the risk of cardiovascular mortality.
authors.forename: Michał
authors.initials: M
authors.lastname: Krysicki
authors.forename: Maria
authors.initials: M
authors.lastname: Jaworska
authors.forename: Bozena
authors.initials: B
authors.lastname: Popowicz
authors.forename: Joanna
authors.initials: J
authors.lastname: Jankiewicz-Wika
authors.forename: Mariusz
authors.initials: M
authors.lastname: Klencki
authors.forename: Dorota
authors.initials: D
authors.lastname: Słowińska-Klencka
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001795:Blood Pressure Determination; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000401:mortality* / Q000517:prevention & control; D002784:Cholesterol / Q000097:blood; D015897:Comorbidity; D005067:Euthyroid Sick Syndromes / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy* / Q000453:epidemiology* / Q000378:metabolism; D015994:Incidence; D024821:Metabolic Syndrome / Q000453:epidemiology; D008875:Middle Aged; D012307:Risk Factors; D015996:Survival Rate; D013974:Thyroxine / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D002784:Cholesterol; D013974:Thyroxine